Novo Nordisk partners with OpenAI

Novo Nordisk said on April 14 that it is partnering with OpenAI to use artificial intelligence across drug discovery, manufacturing and commercial operations. (novonordisk.com) The Danish drugmaker said the goal is to bring new treatments to patients faster by using AI to analyze large datasets, spot patterns and test research ideas more quickly. (cnbc.com) Novo said pilot programs are starting in research and development, manufacturing and commercial teams, with broader integration targeted by the end of 2026. (pharmaceutical-technology.com) The company said OpenAI’s tools will be used beyond the lab, including in supply chain, distribution and other global operations tied to getting medicines to market. (manufacturingchemist.com) Drug discovery starts with a basic problem: researchers must sift through huge amounts of biology and chemistry data to find signals that might point to a useful medicine. Novo said AI can help process that information at a scale that was previously out of reach in everyday work. (cnbc.com) Novo tied the partnership directly to obesity and diabetes, the markets behind Ozempic and Wegovy, saying there are still therapies waiting to be found for millions of patients. (cnbc.com) The agreement also includes workforce training. Novo said OpenAI will help improve AI literacy across its global employee base, alongside data governance and human oversight meant to keep the systems compliant and controlled. (pharmaceutical-technology.com) (manufacturingchemist.com) The deal adds OpenAI to a growing list of technology partners inside large pharmaceutical companies. Trade coverage said OpenAI has also signed life-sciences deals involving Eli Lilly, Moderna, Sanofi and Thermo Fisher Scientific. (pharmaceutical-technology.com) (manufacturingchemist.com) Novo was already building AI work with Nvidia before this announcement. CNBC reported that partnership used Denmark’s Gefion sovereign AI supercomputer to build custom models and agents for early research and clinical development. (cnbc.com) Investors initially welcomed the announcement. CNBC reported Novo Nordisk shares rose 2.8% shortly after the opening bell on April 14, even as analysts cautioned that AI’s nearer-term gains may come from operations and clinical trial work as much as from discovering entirely new drugs. (cnbc.com) For now, Novo has described a broad operating partnership rather than a single drug program. The next test is whether those pilots produce faster research, smoother manufacturing and shorter timelines from bench to patient. (novonordisk.com) (pharmaceutical-technology.com)